))
Using AI and Synthetic Biology to Go Where Antibody Therapies Can’t
Manage episode 446655291 series 3551733
A tartalmat a Levine Media Group biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Levine Media Group vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
Monoclonal antibodies have been an important addition to the biomedical arsenal, but these therapies have limited ability to target a group of cell surface receptors known as GPCRs. Aikium is developing a new class of therapies known as SeqR proteins that offer an alternative to antibody-based drugs and can bind to intrinsically disordered regions of targeted GPCRs that were previously considered undruggable. Venkatesh Mysore, co-founder and CTO of Aikium, sits down with Amar Drawid to discuss how the company is using AI and synthetic biology to discover SeqR protein therapeutics to treat cancer, auto-immune diseases, and neuro-inflammatory disorders.
19 epizódok
Megosztás
